GlassScriptPhysician profile
Ganesh U Rau
NPI 1174671291
$10,806.99
in general payments reported to CMS, 2019-2025
25 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $771 · 2021: $1,332 · 2022: $1,672 · 2023: $2,559 · 2024: $1,894 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,698.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,948.58 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $1,164.55 | 2019-2025 | Cequa |
| Allergan, INC. | $872.66 | 2019-2021 | |
| Biotissue Holdings INC. | $803.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $790.60 | 2019-2023 | |
| Glaukos Corporation | $783.18 | 2021-2025 | Idosetr, Istent Infinite, Idose |
| Oyster Point Pharma, INC. | $705.64 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $695.99 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $616.07 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $474.26 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Dompe US, INC. | $402.03 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $346.00 | 2023-2025 | Rocklatan, Tryptyr, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $244.42 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $195.77 | 2019-2022 | |
| Harrow Eye, LLC | $155.99 | 2024-2025 | Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $139.47 | 2019-2023 | Tobradex St |
| Johnson & Johnson Surgical Vision, INC. | $128.69 | 2021-2025 | Tecnis Iol |
| Ocular Therapeutix, INC. | $112.03 | 2021-2025 | Dextenza |
| Travere Therapeutics, INC. | $94.55 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $36.27 | 2019 | |
| Shire North American Group INC | $30.00 | 2019 | |
| Coopervision INC. | $18.36 | 2023 | Paragon Crt |
| Mallinckrodt Hospital Products INC. | $17.99 | 2024 | Acthar |
| Nova Eye, INC. | $16.76 | 2024 | |
| Horizon Therapeutics Plc | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ganesh Rau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.